Cart
sales@molnova.com
CPG-52364
CAS No. 1093135-60-4
CPG-52364( CPG 52364 | CPG52364 )
Catalog No. M10358 CAS No. 1093135-60-4
CPG-52364 (CPG52364) is an orally available, small molecule TLR7/8/9 antagonist for the treatment of systemic lupus erythematosus and other autoimmune disorders.
Purity : >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
| Size | Price / USD | Stock | Quantity |
| 5MG | 387 | In Stock |
|
| 10MG | 572 | In Stock |
|
| 25MG | 888 | In Stock |
|
| 50MG | 1224 | In Stock |
|
| 100MG | 1647 | In Stock |
|
| 200MG | Get Quote | In Stock |
|
| 500MG | Get Quote | In Stock |
|
| 1G | Get Quote | In Stock |
|
Biological Information
-
Product NameCPG-52364
-
NoteResearch use only, not for human use.
-
Brief DescriptionCPG-52364 (CPG52364) is an orally available, small molecule TLR7/8/9 antagonist for the treatment of systemic lupus erythematosus and other autoimmune disorders.
-
DescriptionCPG-52364 (CPG52364) is an orally available, small molecule TLR7/8/9 antagonist for the treatment of systemic lupus erythematosus and other autoimmune disorders.Other Indication Phase 1 Discontinued.
-
In Vitro——
-
In Vivo——
-
SynonymsCPG 52364 | CPG52364
-
PathwayImmunology/Inflammation
-
TargetTLR
-
RecptorTLR
-
Research AreaOther Indications
-
IndicationOther Disease
Chemical Information
-
CAS Number1093135-60-4
-
Formula Weight492.624
-
Molecular FormulaC27H36N6O3
-
Purity>98% (HPLC)
-
Solubility——
-
SMILESCN1CCN(C2=CC=C(C3=NC(NCCN4CCOCC4)=C5C=C(OC)C(OC)=CC5=N3)C=C2)CC1
-
Chemical Name6,7-dimethoxy-2-(4-(4-methylpiperazin-1-yl)phenyl)-N-(2-morpholinoethyl)quinazolin-4-amine
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
1. Watanabe M, et al. ACS Med Chem Lett. 2014 Oct 2;5(11):1235-9.
2. Parkinson T. Curr Opin Mol Ther. 2008 Feb;10(1):21-31.
molnova catalog
related products
-
CU-115
CU-115 is a selective antagonist of TLR8 with IC50s of 1.04 μM and >50 μM for TLR8 and TLR7, respectively.
-
4-Methylayapin
4-Methylayapin
-
BBIQ
BBIQ is a powerful vaccine adjuvant that enhances innate immune responses and it is a imidazoquinoline compound and a potent and selectively toll-like receptor 7 (TLR7) agonist with an EC50 of 59.1 nM for human TLR7.
